141 related articles for article (PubMed ID: 17926180)
1. A potential role for HSP90 inhibitors in the treatment of JAK2 mutant-positive diseases as demonstrated using quantitative flow cytometry.
Bareng J; Jilani I; Gorre M; Kantarjian H; Giles F; Hannah A; Albitar M
Leuk Lymphoma; 2007 Nov; 48(11):2189-95. PubMed ID: 17926180
[TBL] [Abstract][Full Text] [Related]
2. Heat shock protein 90 inhibitor is synergistic with JAK2 inhibitor and overcomes resistance to JAK2-TKI in human myeloproliferative neoplasm cells.
Fiskus W; Verstovsek S; Manshouri T; Rao R; Balusu R; Venkannagari S; Rao NN; Ha K; Smith JE; Hembruff SL; Abhyankar S; McGuirk J; Bhalla KN
Clin Cancer Res; 2011 Dec; 17(23):7347-58. PubMed ID: 21976548
[TBL] [Abstract][Full Text] [Related]
3. Mechanisms of Resistance to JAK2 Inhibitors in Myeloproliferative Neoplasms.
Meyer SC
Hematol Oncol Clin North Am; 2017 Aug; 31(4):627-642. PubMed ID: 28673392
[TBL] [Abstract][Full Text] [Related]
4. Genetic resistance to JAK2 enzymatic inhibitors is overcome by HSP90 inhibition.
Weigert O; Lane AA; Bird L; Kopp N; Chapuy B; van Bodegom D; Toms AV; Marubayashi S; Christie AL; McKeown M; Paranal RM; Bradner JE; Yoda A; Gaul C; Vangrevelinghe E; Romanet V; Murakami M; Tiedt R; Ebel N; Evrot E; De Pover A; Régnier CH; Erdmann D; Hofmann F; Eck MJ; Sallan SE; Levine RL; Kung AL; Baffert F; Radimerski T; Weinstock DM
J Exp Med; 2012 Feb; 209(2):259-73. PubMed ID: 22271575
[TBL] [Abstract][Full Text] [Related]
5. Heterodimeric JAK-STAT activation as a mechanism of persistence to JAK2 inhibitor therapy.
Koppikar P; Bhagwat N; Kilpivaara O; Manshouri T; Adli M; Hricik T; Liu F; Saunders LM; Mullally A; Abdel-Wahab O; Leung L; Weinstein A; Marubayashi S; Goel A; Gönen M; Estrov Z; Ebert BL; Chiosis G; Nimer SD; Bernstein BE; Verstovsek S; Levine RL
Nature; 2012 Sep; 489(7414):155-9. PubMed ID: 22820254
[TBL] [Abstract][Full Text] [Related]
6. The Development and Use of Janus Kinase 2 Inhibitors for the Treatment of Myeloproliferative Neoplasms.
Hobbs GS; Rozelle S; Mullally A
Hematol Oncol Clin North Am; 2017 Aug; 31(4):613-626. PubMed ID: 28673391
[TBL] [Abstract][Full Text] [Related]
7. Curcumin induces apoptosis in JAK2-mutated cells by the inhibition of JAK2/STAT and mTORC1 pathways.
Petiti J; Rosso V; Lo Iacono M; Panuzzo C; Calabrese C; Signorino E; Pironi L; Cartellà A; Bracco E; Pergolizzi B; Beltramo T; Fava C; Cilloni D
J Cell Mol Med; 2019 Jun; 23(6):4349-4357. PubMed ID: 31033209
[TBL] [Abstract][Full Text] [Related]
8. Homoharringtonine affects the JAK2-STAT5 signal pathway through alteration of protein tyrosine kinase phosphorylation in acute myeloid leukemia cells.
Tong H; Ren Y; Zhang F; Jin J
Eur J Haematol; 2008 Oct; 81(4):259-66. PubMed ID: 18616510
[TBL] [Abstract][Full Text] [Related]
9. Sensitivity and resistance of JAK2 inhibitors to myeloproliferative neoplasms.
Bhagwat N; Levine RL; Koppikar P
Int J Hematol; 2013 Jun; 97(6):695-702. PubMed ID: 23670175
[TBL] [Abstract][Full Text] [Related]
10. American Association for Cancer Research--97th annual meeting.
Kondo Y; Kondo S
IDrugs; 2006 Jun; 9(6):409-11. PubMed ID: 16752309
[No Abstract] [Full Text] [Related]
11. JAK1-dependent transphosphorylation of JAK2 limits the antifibrotic effects of selective JAK2 inhibitors on long-term treatment.
Zhang Y; Liang R; Chen CW; Mallano T; Dees C; Distler A; Reich A; Bergmann C; Ramming A; Gelse K; Mielenz D; Distler O; Schett G; Distler JHW
Ann Rheum Dis; 2017 Aug; 76(8):1467-1475. PubMed ID: 28478401
[TBL] [Abstract][Full Text] [Related]
12. [HSP90 inhibitor 17-AAG plays an important role in JAK3/STAT5 signaling pathways in HTLV-1 infection cell line HUT-102].
Yang QQ; Tan H; Fu ZP; Ma Q; Song JL
Zhonghua Xue Ye Xue Za Zhi; 2017 Aug; 38(8):710-715. PubMed ID: 28954352
[No Abstract] [Full Text] [Related]
13. Multifaceted intervention by the Hsp90 inhibitor ganetespib (STA-9090) in cancer cells with activated JAK/STAT signaling.
Proia DA; Foley KP; Korbut T; Sang J; Smith D; Bates RC; Liu Y; Rosenberg AF; Zhou D; Koya K; Barsoum J; Blackman RK
PLoS One; 2011 Apr; 6(4):e18552. PubMed ID: 21533169
[TBL] [Abstract][Full Text] [Related]
14. Heat shock protein 90 inhibition is cytotoxic to primary AML cells expressing mutant FLT3 and results in altered downstream signalling.
Al Shaer L; Walsby E; Gilkes A; Tonks A; Walsh V; Mills K; Burnett A; Rowntree C
Br J Haematol; 2008 May; 141(4):483-93. PubMed ID: 18373709
[TBL] [Abstract][Full Text] [Related]
15. A novel small molecule deubiquitinase inhibitor blocks Jak2 signaling through Jak2 ubiquitination.
Kapuria V; Levitzki A; Bornmann WG; Maxwell D; Priebe W; Sorenson RJ; Showalter HD; Talpaz M; Donato NJ
Cell Signal; 2011 Dec; 23(12):2076-85. PubMed ID: 21855629
[TBL] [Abstract][Full Text] [Related]
16. The heat-shock protein 90 inhibitor, geldanamycin, induces apoptotic cell death in Epstein-Barr virus-positive NK/T-cell lymphoma by Akt down-regulation.
Jeon YK; Park CH; Kim KY; Li YC; Kim J; Kim YA; Paik JH; Park BK; Kim CW; Kim YN
J Pathol; 2007 Oct; 213(2):170-9. PubMed ID: 17768706
[TBL] [Abstract][Full Text] [Related]
17. Preclinical characterization of atiprimod, a novel JAK2 AND JAK3 inhibitor.
Quintás-Cardama A; Manshouri T; Estrov Z; Harris D; Zhang Y; Gaikwad A; Kantarjian HM; Verstovsek S
Invest New Drugs; 2011 Oct; 29(5):818-26. PubMed ID: 20372971
[TBL] [Abstract][Full Text] [Related]
18. Comparison of two homogeneous cell-based kinase assays for JAK2 V617F: SureFire pSTAT5 and GeneBLAzer fluorescence resonance energy transfer assays.
Qian J; Mason JL; Holskin BP; Murray KA; Meyer SL; Ator MA; Angeles TS
Assay Drug Dev Technol; 2012 Apr; 10(2):212-7. PubMed ID: 22132729
[TBL] [Abstract][Full Text] [Related]
19. Alleviating neurodegeneration by an anticancer agent: an Hsp90 inhibitor (17-AAG).
Waza M; Adachi H; Katsuno M; Minamiyama M; Tanaka F; Sobue G
Ann N Y Acad Sci; 2006 Nov; 1086():21-34. PubMed ID: 17185503
[TBL] [Abstract][Full Text] [Related]
20. The HSP90 inhibitor 17-AAG synergizes with doxorubicin and U0126 in anaplastic large cell lymphoma irrespective of ALK expression.
Georgakis GV; Li Y; Rassidakis GZ; Medeiros LJ; Younes A
Exp Hematol; 2006 Dec; 34(12):1670-9. PubMed ID: 17157164
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]